22 Jul Bayer
Tina Self, Senior Vice President, Global Head of Biologics Manufacturing; Berkeley Site Head
Oct. 8 | 1:15pm | FLW Ballroom F
Leverkusen, Germany
(NASDAQ:BAYN)
Bayer has invested €3.5 billion in the build-up of its cell and gene therapy pipeline. Its innovation engines, BlueRock Therapeutics and AskBio, have exciting programs across multiple indications in preclinical through Phase 2. The company has collaborations with Mammoth Biosciences and Acuitas in the CGT space as well. Bayer has partnered with BlueRock to industrialize processes and will manufacturer for late stage/commercial supply of DA01, BlueRock’s Parkinson’s candidate, and supports pre-clinical development programs at both BlueRock and AskBio. Bayer is also working with Cytiva to set industry standards with the first end-to-end allogeneic CT manufacturing platform. In our mission’s spirit, “Health for All”, Bayer has created a CGT-focused incubator in Cambridge, MA to support startups; additional global locations are coming online. We are also helping external innovators make their therapeutic candidates a reality through BioPartnering Solutions you can leverage industry-leading biotech process development and biomanufacturing capabilities.
